| GTO ID | GTC2891 |
| Trial ID | NCT05192460 |
| Disease | Esophageal Cancer | Liver Cancer | Stomach Cancer |
| Therapy | mRNA vaccine |
| Treatment | PGV002 |
| Co-treatment | PD-1/L1 |
| Phase | Not Applicable |
| Recruitment status | Recruiting |
| Title | A Dose-Escalation and Dose-Expansion Study Evaluating the Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer |
| Year | 2022 |
| Country | China |
| Company sponsor | jianming xu |
| Other ID(s) | XKY-1005 |
| Cohort 1 | |||||||
|
|||||||